Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
Anthos Therapeutics, Inc. · with Novartis Pharmaceuticals · NCT05712200
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 65+ · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Phase 3
- Target enrollment
- 2500
- US sites recruiting
- 132
- Study start
- December 27, 2022
- Record last updated
- July 13, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
A study to evaluate the effect of abelacimab relative to placebo on the rate of ischemic stroke or systemic embolism (SE) in patients with Atrial Fibrillation (AF) who have been deemed by their responsible physicians or by their own decision to be unsuitable for oral anticoagulation therapy.
Being studied: Abelacimab; Placebo
Conditions: Atrial Fibrillation (AF)
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Patient is able to understand and has provided written informed consent to participate in the trial
- Diagnosed Atrial Fibrillation (AF) or atrial flutter (documented on an electrocardiogram (ECG) or monitor recording)
- Age 65-74 and a CHA2DS2VASc ≥4 OR age ≥75 and a CHA2DS2VASc ≥3
- Patient is judged by the responsible physician to be unsuitable for oral anticoagulation because the risks outweigh the benefits or the patient is unwilling to take oral anticoagulation AND this determination was made prior to and independent of the study
- At least 1 bleeding risk factor such as severe renal insufficiency, planned daily use of antiplatelet medication for the duration of the trial, history of bleeding from a critical area, or other conditions associated with increased risk of bleeding such as chronic nonsteroidal anti-inflammatory drug (NSAID) use, frailty or multiple falls
- Patient is judged by the responsible physician to be unsuitable for left atrial appendage (LAA) closure or occlusion device, an approved device is not available, or the patient is unwilling to undergo the procedure AND this determination was made prior to and independent of the study
Exclusion Criteria
- AF due to an ongoing acute reversible cause (e.g., cardiac surgery, pulmonary embolism (PE), untreated hyperthyroidism, alcohol use)
- Patients who within 60 days prior to randomization (1) received a vitamin K antagonists (VKA) (e.g., warfarin, phenprocoumon, acenocoumarol) or a direct oral anticoagulant (DOAC) such as, dabigatran, rivaroxaban, apixaban, or edoxaban or (2) were newly diagnosed with AF
- Patients with an intracranial or intraocular bleed within the 3 months prior to screening or any history of spontaneous intracerebral hemorrhage at any time in the absence of antithrombotic treatment
- Any stroke within 14 days before randomization or transient ischemic attack (TIA) within 3 days before randomization
- Mechanical heart valve or valve disease that is expected to require mechanical valve replacement intervention (surgical or invasive) during the course of the study
- Patients on dialysis at screening or who are planned to start dialysis within 6 months
Other protocol defined Inclusion/Exclusion criteria may apply
Recruiting US locations
Anthos Investigative Site 1040
Birmingham, AL 35205
Site contact: Ashley Gilmore · agilmore@uabmc.edu
Anthos Investigational site 9939
Birmingham, AL 35233
Site contact: Fadi Hage
Anthos Investigative Site 1041
Mobile, AL 36608
Site contact: Cheryl Flock · cflock@cbflockresearch.org
Anthos Investigative Site 1099
Peoria, AZ 85381
Site contact: Jocelyn Luque · jluque@suncitytrials.com
Anthos Investigative Site 9906
Phoenix, AZ 85018
Site contact: Nicole Ossino · nicole@eliteclinicalstudies.com
Anthos Investigative Site 9927
Yuma, AZ 85365
Site contact: Katie Welch · katie@yumaclinicaltrials.com
Anthos Investigative Site 9929
Huntington Beach, CA 92648
Site contact: Maria Trisa Palmares · tpalmares@nicresearch.com
Anthos Investigative Site 9959
Imperial, CA 92251
Site contact: Aaron Soto · aaron@biosolutionsresearch.com
Anthos Investigative Site 9921
Lancaster, CA 93534
Site contact: Aileen Doriguzzi · adoriguzzi@chemidox.com
Anthos Investigative Site 1078
Loma Linda, CA 92357
Site contact: Agnes Lee · agnes.lee2@va.gov
Anthos Investigative Site 1077
Los Angeles, CA 90022
Site contact: Yoltic Flores · flores@eastsideclinicalresearch.org
Anthos Investigational site 9821
Orange, CA 92868
Site contact: Karen Cruz · karen.cruz@damg.site
Anthos Investigative Site 1071
San Dimas, CA 91773
Site contact: Syeda Naqvi · snaqvi@nariresearch.com
Anthos Investigative Site 9938
Santa Rosa, CA 95405
Site contact: Julie Rosenberg · jrosenberg@northbayclinicalresearch.com
Anthos Investigative Site 9908
South Gate, CA 90280
Site contact: John Park · johnnie@charityhealth.net
Anthos Investigative Site 9907
Vista, CA 92081
Site contact: Mohammed Khalil · mohamed.khalil@bluecoastcardiology.com
Anthos Investigative Site 1095
Aurora, CO 80045
Site contact: Jennifer Golden · jennifer.golden@va.gov
Anthos Investigative Site 9922
Golden, CO 80228
Site contact: David Bailey · dbailey@chvpc.com
Anthos Investigative Site 1012
Stamford, CT 06905
Site contact: Stephanie Seredenko · sseredenko@cafconline.com
Anthos Investigative Site 9934
Altamonte Springs, FL 32714
Site contact: Megan Bodiford · mbodiford@heartorlando.com
Anthos Investigative Site 1013
Boca Raton, FL 33486
Site contact: Esthefany Jabbour · esthefany@fwdclinical.com
Anthos Investigational site 9810
Bradenton, FL 34209
Site contact: Mirabella Miranda · Mirabella.miranda@novaclinicalresearch.com
Anthos Investigational site 9818
Clearwater, FL 33756
Site contact: Delia Johnson · delia.johnson@baycare.org
Anthos Investigative Site 1025
Clearwater, FL 33756
Site contact: Carolyn Rembish · rembishc@cccheart.com
Anthos Investigative Site 1022
Clearwater, FL 33777
Site contact: Teresa Jones · jonest@cccheart.com
Anthos Investigative Site 1019
Daytona Beach, FL 32114
Site contact: Jennifer Langdon · jlangdon@daytonaheart.com
Anthos Investigative Site 9936
Hialeah, FL 33012
Site contact: Ana Fernandez · afernandez@evolutionresearchcenter.com
Anthos Investigative Site 9804
Hollywood, FL 33020
Site contact: Ariel Soffer
Anthos Investigative Site 1083
Hollywood, FL 33024
Site contact: Ana Gonzalez · agonzalez@innovativehealthmd.com
Anthos Investigational site 9808
Jacksonville, FL 32209
Site contact: Hayley Cheatwood · Hayley.cheatwood@ufhealth.org
Anthos Investigational site 9813
Jacksonville, FL 32256
Site contact: Leticia Robinson · lrobinson@cnshealthcare.com
Anthos Investigational site 9828
Jacksonville, FL 32256
Site contact: Christopher Chan · cchan@firstcoastcardio.com
Anthos Investigative Site 9904
Lake Mary, FL 32746
Site contact: Kiran Penta · kiran@aorcorp.com
Anthos Investigative Site 1093
Lutz, FL 33558
Site contact: Christian Kelbaugh · christian.kelbaugh@baycare.org
Anthos Investigative Site 9933
Miami, FL 33145
Site contact: Milene Garcia · mg.medoneclinicalresearch@outlook.com
Anthos Investigational site 9823
Miami Lakes, FL 33014
Site contact: Anabel Nuez · adelanuez@inpatientresearch.com
Anthos Investigative Site 9944
Ocala, FL 34471
Site contact: Arleana Brown · arleana.brown@morganmmc.com
Anthos Investigative Site 9940
Ocala, FL 34474
Site contact: Karen Perry · karen@ehsfamily.com
Anthis Investigational site 9811
Pensacola, FL 32503
Site contact: Jennifer Lehman · jennifer.lehmann@bhcpns.org
Anthos Investigational site9830
Pensacola, FL 32504
Site contact: Danielle struckel · danielle.struckel@ascension.org
Anthos Investigative Site 1026
Safety Harbor, FL 34695
Site contact: Laura Jenkins · jenkinsl@cccheart.com
Anthos Investigative Site 1002
Saint Augustine, FL 32086
Site contact: Keearah Galvao · keearah.galvao@eastcoastresearch.net
Anthos Investigative Site 1004
Saint Augustine, FL 32086
Site contact: Lucy Herter · lherter@encoredocs.com
Anthos Investigative Site 1044
Tamarac, FL 33321
Site contact: Enrique Fernandez · enrique.fernandez@careaccess.com
Anthos Investigative Site 1088
Tamarac, FL 33321
Site contact: Diego Sanchez · dsanchez@dhnrc.com
Anthos Investigative Site 9911
The Villages, FL 32162
Site contact: Stephanie Smith · stephanie.smith@globalaes.com
Anthos Investigative Site 1033
Macon, GA 31201
Site contact: Heather Maschenik · hmaschenik@gacri.com
Anthos Investigative Site 1003
Suwanee, GA 30024
Site contact: Charlotte Mall · charlotte@nscresearch.org
Anthos Investigative Site 9953
Tucker, GA 30084
Site contact: Andrew Mayer · amayer@ahsmed.com
Anthos Investigative Site 1030
Park Ridge, IL 60068
Site contact: Loria Awadallah · loria.awadallah@amr-clinical.com
Anthos Investigative Site 9932
Rockford, IL 61107
Site contact: Barbara Connors · barbara.l.connors@osfhealthcare.org
Anthos Investigative Site 9925
Winfield, IL 60190
Site contact: Ahad Ahmad · ahad.ahmad@accellacare.com
Anthos Investigative Site 9915
Evansville, IN 47714
Site contact: Abigail Hudson · abigail.hudson@globalaes.com
Anthos Investigative Site 1098
Merrillville, IN 46410
Site contact: Rehan Ahmed · rahmed@indianaclinicalresearch.com
Anthos Investigative Site 9956
West Des Moines, IA 50266
Site contact: Ahymad Lee · alee@innovoresearch.com
Anthos Investigative Site 9958
Hutchinson, KS 67502
Site contact: Amy Martens · amartens@innovoresearch.com
Anthos Investigative Site 1016
Wichita, KS 67207
Site contact: Erina Kulitek · Erina.Kutilek@amr-clinical.com
Anthos Investigational site 9968
Eunice, LA 70535
Site contact: Rechell Barzas · rechell.barzas@careaccess.com
Anthos Investigative Site 1043
Shreveport, LA 71103
Site contact: Iris Cahn · gcahn.cvsolutions@gmail.com
Anthos Investigational site 9803
West Monroe, LA 71291
Site contact: Nina Parrot · nparrott76@gmail.com
+ 72 more on the official record.
Study contacts (from the official record)
- Anthos Therapeutics a Novartis Company · 1-888-669-6682 · novartis.email@novartis.com
Similar studies in Alabama
All heart & blood pressure studies in Alabama →- RecruitingHealthy volunteersPhase 1
Chronic Hypertension and Pregnancy 2 (CHAP2) Pilot Project
University of Alabama at Birmingham
- Location
- Birmingham, AL
- Eligibility basics
- Ages 14–89 · Women only
- Recruiting
Assessment of CCM in HF With Higher Ejection Fraction
Impulse Dynamics
- Location
- Birmingham, AL + 64 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)
Merck Sharp & Dohme LLC
- Location
- Alexander City, AL + 23 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
Prevail Global Study
Medtronic Vascular
- Location
- Birmingham, AL + 53 other US sites
- Eligibility basics
- Ages 18+